Terns Pharmaceuticals, Inc. TERN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

46/100

3/6 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Terns Pharmaceuticals, Inc. (TERN) generated $-82.18M in operating cash flow for fiscal year 2025. After capital expenditures of $0.00, free cash flow was $-82.18M.

Cash conversion ratio was 0.85x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (40/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.85x suggests some earnings are non-cash items

Overall SharesGrow Score: 45/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score

46/100

SG Score

View full scorecard →

✓

VALUE

60/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

61/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

40/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Terns Pharmaceuticals, Inc. Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$-82.18M	$-82.18M	$-70.02M	$-67.39M	$-49.11M
Capital Expenditure	$0.00	$0.00	$-42K	$-52K	$-275K
Free Cash Flow	$-82.18M	$-82.18M	$-70.06M	$-67.44M	$-49.38M